Serial #79388821
LIVE

Serial Number

79388821

Owner

Telix Pharmaceuticals Limited

Attorney

Andrew S. Ehard

Filing Date

Sep 22, 2023

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79388821 Trademark

Serial Number: 79388821 • Registration: 7772646

Serial #79388821 is a trademark filed by Telix Pharmaceuticals Limited on September 22, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Telix Pharmaceuticals Limited (38 trademarks)

Suite 401, 55 Flemington Road

Entity Type: 99

Trademark Details

Filing Date

September 22, 2023

Registration Date

April 29, 2025

Published for Opposition

March 11, 2025

Goods & Services

Exploitation of intellectual property rights, namely, licensing of intellectual property rights; licensing of intellectual property

Radioactive elements for scientific purposes; radioactive preparations for scientific purposes; chemicals for use in the manufacture of radiopharmaceutical products; chemical products for radioactive labelling

Advertising services; business advisory services relating to product development; business consultancy; retail and wholesale store services featuring pharmaceutical, veterinary and sanitary preparations and medical supplies; intermediary business services relating to the commercialization of goods, namely, procuring of contracts for third parties for the purchase and sale of goods

Provision of scientific information in the field of pharmaceuticals and clinical trials; scientific and technical analysis, namely, scientific research and analysis in the field of pharmaceuticals; scientific research consultancy; scientific research; scientific research in the field of pharmacy; medical research; research and development of new products; laboratory research relating to pharmaceuticals; advisory services being product development consultation relating to immunological products; research and development of new techniques for radiolabelling of pharmaceutical products

Chemicals for pharmaceutical use in the nature of chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer and diseases associated with cellular proliferation; pharmaceuticals for the treatment of cancer and diseases associated with cellular proliferation; Pharmaceutical preparations for the treatment of cancer and diseases associated with cellular proliferation; pharmaceutical preparations for the treatment of cancer; radiopharmaceutical products, namely, radiopharmaceutical diagnostic preparations and radiopharmaceutical treatment preparations for the treatment of cancer and diseases associated with cellular proliferation; chemicals being radiopharmaceuticals for diagnostic uses; radiopharmaceutical drug preparations for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radiopharmaceutical products for diagnostic uses; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; radioactive elements, isotopes, preparations and reagents for radioactive labelling of pharmaceutical products for medical use; Diagnostic radiopharmaceutical preparations

Apparatus for administering pharmaceuticals for the treatment, prevention, or diagnosis of cancer, namely, medical apparatus for introducing pharmaceutical preparations into the human body for the treatment, prevention, or diagnosis of cancer; apparatus for medical purposes for the treatment, prevention, or diagnosis of cancer, namely, injection needles, injection syringes, and radiological apparatus for the treatment, prevention, or diagnosis of cancer; medical apparatus for the treatment of cancer; diagnostic imaging apparatus for medical use; pharmaceutical instruments, namely, radiological apparatus for medical purposes, medical apparatus for the treatment of cancer and diseases associated with cellular proliferation, and imaging apparatus for medical use for diagnosing medical conditions; applicators for pharmaceutical preparations, namely, applicators for pharmaceutical preparations sold without medication

Custom manufacture of pharmaceuticals, namely, radiopharmaceuticals; Custom manufacture of pharmaceuticals, namely, radiolabelling of pharmaceuticals

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jan 22, 2026 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jan 1, 2026 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 5, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 19, 2025 FICS
FINAL DISPOSITION PROCESSED
Nov 19, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 29, 2025 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jul 26, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 7, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jul 7, 2025 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 29, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 29, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 11, 2025 NPUB
PUBLISHED FOR OPPOSITION
Mar 11, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 5, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 14, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 14, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 14, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 14, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 14, 2025 CNEA
EXAMINER'S AMENDMENT ENTERED
Feb 10, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 10, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 10, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 10, 2025 CNEA
ASSIGNED TO EXAMINER
Jan 26, 2025 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 7, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 7, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 7, 2024 TROA
REFUSAL PROCESSED BY IB
May 1, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 9, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 9, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 21, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 20, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 14, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 16, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 9, 2024 REPR